TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30819157

Group type: EXPERIMENTAL
Intervention: Increasing government subsidies
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Implementing clinical pathways
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Removing drug mark-ups
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Salary system reform
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Current income level satisfaction
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Adjusting pricing policies
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Removing drug markups
Number of subjects: 178
Study: 29729672

Group type: EXPERIMENTAL
Intervention: Oily fish intake
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: APOE genotype
Number of subjects: 306
Study: 26621521

Group type: EXPERIMENTAL
Intervention: YOCAS©® yoga
Number of subjects: 328

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 328
Study: 25442152

Group type: EXPERIMENTAL
Intervention: Bimodal transcranial direct current stimulation (tDCS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study: 23342565

Group type: EXPERIMENTAL
Intervention: 1% NaOCl
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 2.5% NaOCl
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 5% NaOCl
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 10% NaOCl
Number of subjects: 84

Group type: COMPARATOR
Intervention: Acid Etchant (Control)
Number of subjects: 84
Study: 20515217

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Interpersonal therapy
Number of subjects: 72
Study: 18984393

Group type: EXPERIMENTAL
Intervention: Mini-implants (miniplates, miniscrews, or microscrews)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Traditional anchorage preparation with a transpalatal arch and headgear
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Mini-implants
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Skeletal anchorage
Number of subjects: 47

Group type: COMPARATOR
Intervention: Headgear anchorage
Number of subjects: 47
Study: 15903377

Group type: EXPERIMENTAL
Intervention: Combined resistance and speed training program (COM group)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Conventional resistance training (STR group)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (CON group)
Number of subjects: 35
Study: 12872591

Group type: EXPERIMENTAL
Intervention: Intraoral distraction devices after high LeFort I osteotomies
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Extraoral distraction devices after LeFort I, II and III osteotomies
Number of subjects: 11
Study: 10235220

Group type: EXPERIMENTAL
Intervention: 10 million units alpha-N1 IFN i.m. t.w. for 24 wk (total dose: 720 million units)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 9 million units alpha-2a IFN i.m. t.w. for 4 wk, followed by 18 million units for 12 wk and 9 million units for 8 wk (972 million units)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 2 alpha-2a IFN courses (9 million units i.m. t.w. for 16 and 12 wk separated by a 6-month interval [756 million units])
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Overall response after 34 months (median posttreatment follow-up)
Number of subjects: 72
Study: 8918858

Group type: EXPERIMENTAL
Intervention: Mandatory radiology consultation service
Number of subjects: 2200

Group type: COMPARATOR
Intervention: Control group (no mandatory consultation)
Number of subjects: 2200
Study: 1859007

Group type: EXPERIMENTAL
Intervention: ORG9426 0.12 mg/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: ORG9426 0.16 mg/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: ORG9426 0.20 mg/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: ORG9426 0.6 mg/kg (group 1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: ORG9426 0.6 mg/kg (group 2)
Number of subjects: 80
Study: 6353523

Group type: EXPERIMENTAL
Intervention: L-tryptophan (1 g)
Number of subjects: 54

Group type: COMPARATOR
Intervention: secobarbital (100 mg)
Number of subjects: 54

Group type: COMPARATOR
Intervention: flurazepam (30 mg)
Number of subjects: 54

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 54
Study: 31759660

Group type: EXPERIMENTAL
Intervention: ASSIP (Attempted Suicide Short Intervention Program)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study: 31876460

Group type: EXPERIMENTAL
Intervention: Comprehensive preventive counseling with focus on diet modification followed by remote preventive counseling by phone every two weeks for the first 3 months (total of 6 sessions)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care in Health centers including basic preventive counseling
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 28317415

Group type: EXPERIMENTAL
Intervention: Dabigatran (150 mg twice daily)
Number of subjects: 704

Group type: COMPARATOR
Intervention: Warfarin (target INR 2.0 to 3.0)
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 704

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: Dabigatran and Warfarin
Number of subjects: 704
Study: 26254207

Group type: EXPERIMENTAL
Intervention: Amniotomy group (n = 121)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Repeat-PGE2 group (n = 124)
Number of subjects: 245
Study: 23352688

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 63

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 63
Study: 22677260

Group type: EXPERIMENTAL
Intervention: Docetaxel (D) 75 mg/m² every 3 weeks with prednisone
Number of subjects: 592

Group type: COMPARATOR
Intervention: Docetaxel (D) 75 mg/m² every 3 weeks with prednisone and Risedronate (DR) 30 mg oral once daily
Number of subjects: 592
Study: 20129543

Group type: EXPERIMENTAL
Intervention: Endeavor drug-eluting stent
Number of subjects: 1197

Group type: COMPARATOR
Intervention: Driver bare-metal stent
Number of subjects: 1197
Study: 18019047

Group type: EXPERIMENTAL
Intervention: Antipsychotic drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standardisation in reporting of adverse effects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monitoring of common side-effects
Number of subjects: 0
Study: 15082437

Group type: EXPERIMENTAL
Intervention: 250 mg caffeine
Number of subjects: 19

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 19
Study: 12296840

Group type: EXPERIMENTAL
Intervention: Various cancer treatments; specific interventions not detailed; focus on quality of life measures using standardized schedules.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: User involvement in trials; surveys of recruitment and participation; investigations of patient preferences and experiences.
Number of subjects: 0
Study: 9806651

Group type: EXPERIMENTAL
Intervention: Surgery for local disease
Number of subjects: 1706

Group type: EXPERIMENTAL
Intervention: Surgery alone or in combination with radiation for regional disease
Number of subjects: 1706

Group type: COMPARATOR
Intervention: Radiation for local disease
Number of subjects: 1706

Group type: COMPARATOR
Intervention: Radiation for distant disease
Number of subjects: 1706

Group type: EXPERIMENTAL
Intervention: Chemotherapy for distant disease
Number of subjects: 1706

Group type: EXPERIMENTAL
Intervention: Days spent in hospital for regional disease
Number of subjects: 1706

Group type: EXPERIMENTAL
Intervention: Days spent in hospital for distant disease
Number of subjects: 1706
Study: 7714213

Group type: EXPERIMENTAL
Intervention: Detection of JC virus DNA by PCR in cerebrospinal fluid
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group without progressive multifocal leukoencephalopathy
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: PCR test for JC virus DNA
Number of subjects: 23
Study: 1659438

Group type: EXPERIMENTAL
Intervention: Spiradoline
Number of subjects: 10

Group type: COMPARATOR
Intervention: High dose naloxone
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low dose naloxone
Number of subjects: 10
Study: 7270090

Group type: EXPERIMENTAL
Intervention: Chloroquinaldol (SterosanR vaginal jelly) applied for six days before vacuum aspiration
Number of subjects: 199

Group type: COMPARATOR
Intervention: Control group (291 women)
Number of subjects: 199
Study: 30466805

Group type: EXPERIMENTAL
Intervention: Surgical-radiological assessment
Number of subjects: 1345

Group type: EXPERIMENTAL
Intervention: Surgical-integrated assessment
Number of subjects: 1345

Group type: EXPERIMENTAL
Intervention: Surgical-radiological discordant results
Number of subjects: 1345

Group type: EXPERIMENTAL
Intervention: Surgical-integrated discordant results
Number of subjects: 1345

Group type: EXPERIMENTAL
Intervention: Surgically assessed residual disease
Number of subjects: 1345
Study: 29211194

Group type: EXPERIMENTAL
Intervention: Telephone call - educational
Number of subjects: 511

Group type: EXPERIMENTAL
Intervention: Telephone call - reminder
Number of subjects: 511

Group type: COMPARATOR
Intervention: Comparison group (card with details)
Number of subjects: 511
Study: 25826108

Group type: EXPERIMENTAL
Intervention: Gratitude intervention (gratitude diary and grateful reflection)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Mindfulness intervention (mindfulness diary and Body Scan meditation)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 65
Study: 24078028

Group type: EXPERIMENTAL
Intervention: Continuous intradermal sutures
Number of subjects: 203

Group type: COMPARATOR
Intervention: Interrupted sutures
Number of subjects: 203
Study: 23034962

Group type: EXPERIMENTAL
Intervention: Dietary phylloquinone intake (100 μg phylloquinone/d)
Number of subjects: 1925

Group type: EXPERIMENTAL
Intervention: Increased dietary intake of vitamin K during follow-up
Number of subjects: 1925
Study: 19218829

Group type: EXPERIMENTAL
Intervention: Worry Exposure (WE)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Applied Relaxation (AR)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Waiting List Control
Number of subjects: 73
Study: 18158076

Group type: EXPERIMENTAL
Intervention: LM50/50 + Met
Number of subjects: 315

Group type: COMPARATOR
Intervention: G + Met
Number of subjects: 315
Study: 15465973

Group type: EXPERIMENTAL
Intervention: Low-dose ketamine (0.1 mg/kg)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: High-dose ketamine (0.5 mg/kg)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 45
Study: 11898532

Group type: EXPERIMENTAL
Intervention: Pharmacologic and behavioral components for managing fatigue in MS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self‐report scales and performance‐based measures
Number of subjects: 0
Study: 9519580

Group type: EXPERIMENTAL
Intervention: Less violent theatrical production based on social learning theory and risk-factor reduction
Number of subjects: 0
Study: 8076620

Group type: EXPERIMENTAL
Intervention: Glucose ingestion (50 g at time 0 min and 25 g at time 60 and 120 min)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Sweetened water (control)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Glucose ingestion
Number of subjects: 6
Study: 2510269

Group type: EXPERIMENTAL
Intervention: Rioprostil (300 micrograms b.d. and 600 micrograms nocte)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rioprostil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 0
Study: 215088

Group type: EXPERIMENTAL
Intervention: Artificial diet for 12 months
Number of subjects: 43

Group type: COMPARATOR
Intervention: Conventional diet
Number of subjects: 43
Study: 30796588

Group type: EXPERIMENTAL
Intervention: Canine-guided occlusion (CGO)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bilateral balanced occlusion (BBO)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Transition from BBO to CGO
Number of subjects: 40
Study: 27381968

Group type: EXPERIMENTAL
Intervention: Intentional weight loss through a 3-month intensive behavioral weight management intervention with structured energy-restricted meal plans (1200 or 1500 kcal/day)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 59
Study: 25881462

Group type: EXPERIMENTAL
Intervention: Yiqi Huoxue Decoction (YHD), one dose daily for 14 days
Number of subjects: 46

Group type: COMPARATOR
Intervention: Routine symptomatic treatment (Group A)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Normal control group (18 patients with chronic cough)
Number of subjects: 46
Study: 23703011

Group type: EXPERIMENTAL
Intervention: Segmental motor studies to the second lumbrical (2L)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mixed nerve action potential (MNAP) studies
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Surgical cases (6 patients)
Number of subjects: 20
Study: 20564681

Group type: EXPERIMENTAL
Intervention: Short wave diathermy (SWD)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Analgesic
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 32
Study: 19136484

Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin
Number of subjects: 3096

Group type: COMPARATOR
Intervention: Placebo plus aspirin
Number of subjects: 3096
Study: 17376219

Group type: EXPERIMENTAL
Intervention: Percutaneous retrograde sclerotherapy with hydroxy‐polyaethoxy‐dodecanol
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 38
Study: 15139072

Group type: EXPERIMENTAL
Intervention: Tibetan yoga (TY) intervention, 7 weekly yoga sessions
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Tibetan yoga (TY) intervention
Number of subjects: 39
Study: 11339516

Group type: EXPERIMENTAL
Intervention: meloxicam 7.5 mg
Number of subjects: 1021

Group type: EXPERIMENTAL
Intervention: meloxicam 15 mg
Number of subjects: 1021

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1021

Group type: COMPARATOR
Intervention: diclofenac 150 mg
Number of subjects: 1021
Study: 9255145

Group type: EXPERIMENTAL
Intervention: 111In/90Y-MX-DTPA BrE-3 (6.25 mCi/m2 and 9.25 mCi/m2)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 111In/90Y-MX-DTPA BrE-3
Number of subjects: 6
Study: 8432915

Group type: EXPERIMENTAL
Intervention: rIFN-gamma (50 micrograms/m2 daily subcutaneous injection for 12 weeks)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 31711704

Group type: EXPERIMENTAL
Intervention: 300 mg CoQ10/kg diet
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 600 mg CoQ10/kg diet
Number of subjects: 36

Group type: COMPARATOR
Intervention: 0 mg CoQ10/kg diet (Control)
Number of subjects: 36
Study: 28239945

Group type: EXPERIMENTAL
Intervention: Video clips demonstrating behaviour management techniques for children receiving local anaesthetic
Number of subjects: 86

Group type: COMPARATOR
Intervention: Standard lectures and seminars about behaviour management techniques for children having local anaesthetic
Number of subjects: 86
Study: 27015659

Group type: EXPERIMENTAL
Intervention: Exercise intervention (4-month moderate- to hard-intensity exercise training programme, 29 one-hour classes, twice weekly)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise intervention (4-month moderate- to hard-intensity exercise training programme)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study: 24072136

Group type: EXPERIMENTAL
Intervention: Innovator drug (Omnipaque)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Generic drug (Iopaque)
Number of subjects: 44
Study: 22086352

Group type: EXPERIMENTAL
Intervention: Integral stimuli (pictures with interacting features)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Separable stimuli (pictures with easily discriminable features)
Number of subjects: 0
Study: 21902684

Group type: EXPERIMENTAL
Intervention: Lenalidomide plus dexamethasone (low or high doses)
Number of subjects: 445
Study: 18239240

Group type: EXPERIMENTAL
Intervention: Herbal supplement
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 16627774

Group type: EXPERIMENTAL
Intervention: Nonsupine positions (sitting, squatting, or kneeling/hands-and-knees)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 198
Study: 14709298

Group type: EXPERIMENTAL
Intervention: Intracameral mydriatics
Number of subjects: 60

Group type: COMPARATOR
Intervention: Topical mydriatics
Number of subjects: 60
Study: 10942063

Group type: EXPERIMENTAL
Intervention: Bendamustine 80 mg/m2
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bendamustine 60 mg/m2
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bendamustine 70 mg/m2
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bendamustine (all doses)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bendamustine
Number of subjects: 12
Study: 8782844

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg twice a day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 1619943

Group type: EXPERIMENTAL
Intervention: MMC 12 mg/m2 intravenously on day 1 and OK‐432 5 KE intradermally on days 6, 8, and 11
Number of subjects: 15

Group type: COMPARATOR
Intervention: MMC 12 mg/m2 alone followed by long‐term tegafur
Number of subjects: 15
Study: 3927756

Group type: EXPERIMENTAL
Intervention: WIC prenatal participation
Number of subjects: 7628

Group type: COMPARATOR
Intervention: Non-WIC comparison group
Number of subjects: 7628
Study: 31272483

Group type: EXPERIMENTAL
Intervention: Intraoperative computed tomography (IOCT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preoperative computed tomography (POCT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IOCT
Number of subjects: 0

Group type: COMPARATOR
Intervention: POCT
Number of subjects: 0
Study: 30470229

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/d combined with ezetimibe 10 mg/d (A20E10 group, n=48)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Atorvastatin 40 mg/d (A40 group, n=50)
Number of subjects: 98
Study: 27798770

Group type: EXPERIMENTAL
Intervention: 250 mg SOFE (50 mg hydroxytyrosol)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 500 mg SOFE (100 mg hydroxytyrosol)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 25086401

Group type: EXPERIMENTAL
Intervention: Knee arthroscopy combined with a structured exercise programme (surgery group)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Structured exercise programme alone (non-surgery group)
Number of subjects: 150
Study: 22151023

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg
Number of subjects: 0
Study: 20610550

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (3 cycles of 5 minutes of ischemia alternating with 5 minutes of reperfusion)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lower limb ischemia-reperfusion (tourniquet application)
Number of subjects: 30
Study: 18250251

Group type: EXPERIMENTAL
Intervention: Naltrexone hydrochloride (100 mg) with medical management (MM) alone
Number of subjects: 604

Group type: COMPARATOR
Intervention: Placebo with medical management (MM) alone
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Naltrexone hydrochloride (100 mg) with combined behavioral intervention (CBI)
Number of subjects: 604

Group type: COMPARATOR
Intervention: Placebo with combined behavioral intervention (CBI)
Number of subjects: 604
Study: 15718356

Group type: EXPERIMENTAL
Intervention: DHA+ARA from fish/fungal oil (DHA+ARA(FF))
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: DHA+ARA from egg/fish oil (DHA+ARA(EF))
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control formula
Number of subjects: 60
Study: 11901961

Group type: EXPERIMENTAL
Intervention: Subjects were given the actual probabilities
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Subjects were told if they did well they could leave early
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Competition condition
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Subjects were asked to recommend a strategy for another subject
Number of subjects: 200
Study: 10216805

Group type: EXPERIMENTAL
Intervention: Eprosartan (200‐300 mg b.i.d.)
Number of subjects: 528

Group type: COMPARATOR
Intervention: Enalapril (5‐20 mg o.d.)
Number of subjects: 528
Study: 8801328

Group type: EXPERIMENTAL
Intervention: Dilapress 240 (formulation A) single dose (240 mg)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Dilapress 240 (formulation A) multiple dose (240 mg qd for 6 days)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Cardizem CD (formulation B)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Dilapress 240 (formulation A) single dose (240 mg) without subject 8
Number of subjects: 2

Group type: COMPARATOR
Intervention: Dilapress 240 (formulation A) and Cardizem CD (formulation B)
Number of subjects: 2
Study: 2196146

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine (up to 1.5 mg/kg/day)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Methylphenidate (up to 3.0 mg/kg/day)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both Dextroamphetamine and Methylphenidate
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 31103

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg oral dose before anaesthesia
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (37 patients)
Number of subjects: 46
Study: 31310855

Group type: EXPERIMENTAL
Intervention: Apixaban plus aspirin
Number of subjects: 7392

Group type: EXPERIMENTAL
Intervention: Triple therapy (apixaban, thienopyridine, and aspirin)
Number of subjects: 7392

Group type: COMPARATOR
Intervention: Dual therapy (apixaban plus aspirin)
Number of subjects: 7392

Group type: EXPERIMENTAL
Intervention: TIMI major/minor bleeding
Number of subjects: 7392